Puma Biotechnology

PBYI · NASDAQ

$10.76+$0.55 (+5.39%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $10.21

Latest news

NewsOct 12, 5:18 AM ET
Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcript
Press releaseOct 5, 5:00 PM ETBusiness Wire
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Press releaseSep 17, 4:07 PM ETBusiness Wire
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Press releaseSep 9, 4:11 PM ETBusiness Wire
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
Press releaseSep 3, 5:00 PM ETBusiness Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
NewsAug 6, 4:09 PM ET
Puma Biotechnology Q2 Adj. EPS $0.19 Beats $0.04 Estimate, Sales $53.600M Beat $53.000M Estimate
Press releaseAug 6, 4:05 PM ETBusiness Wire
Puma Biotechnology Reports Second Quarter 2026 Financial Results
Press releaseAug 5, 5:00 PM ETBusiness Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJul 23, 4:10 PM ETBusiness Wire
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results
Press releaseJul 2, 5:03 PM ETBusiness Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJun 3, 5:00 PM ETBusiness Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
NewsMay 7, 4:28 PM ET
Puma Biotechnology Q1 Adj. EPS $(0.04) Beats $(0.13) Estimate, Sales $44.800M Beat $42.000M Estimate
Press releaseMay 7, 4:05 PM ETBusiness Wire
Puma Biotechnology Reports First Quarter 2026 Financial Results
Press releaseMay 6, 5:15 PM ETBusiness Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Press releaseApr 23, 4:15 PM ETBusiness Wire
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
Press releaseApr 2, 5:15 PM ETBusiness Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
NewsFeb 27, 12:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsFeb 26, 6:09 PM ET
UPDATE: Puma Biotechnology Q4 Adj. EPS $0.29 Beats $0.23 Estimate, Sales $75.500M Beat $68.600M Estimate
NewsFeb 26, 4:06 PM ET
Puma Biotechnology Q4 Earnings Report: What Investors Need to Know
NewsFeb 26, 4:06 PM ET
Puma Biotechnology Q4 Adj. EPS $0.30 Beats $0.23 Estimate, Sales $75.500M Beat $68.600M Estimate
Press releaseFeb 26, 4:05 PM ETBusiness Wire
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
NewsFeb 26, 6:11 AM ET
Earnings Scheduled For February 26, 2026
Press releaseFeb 23, 4:15 PM ETBusiness Wire
Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference
Press releaseFeb 12, 4:07 PM ETBusiness Wire
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results
Press releaseFeb 4, 5:05 PM ETBusiness Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJan 7, 5:15 PM ETBusiness Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Press releaseDec 22, 4:10 PM ETBusiness Wire
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)
Press releaseDec 2, 5:15 PM ETBusiness Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
NewsNov 10, 12:07 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
Press releaseNov 7, 5:05 PM ETBusiness Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
NewsNov 6, 4:06 PM ET
Puma Biotechnology Q3 Adj. EPS $0.21 Beats $0.04 Estimate, Sales $54.500M Beat $51.000M Estimate
Press releaseNov 6, 4:05 PM ETBusiness Wire
Puma Biotechnology Reports Third Quarter 2025 Financial Results
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
Press releaseOct 23, 4:10 PM ETBusiness Wire
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Press releaseOct 2, 5:21 PM ETBusiness Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Press releaseSep 4, 5:25 PM ETBusiness Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Press releaseAug 7, 4:05 PM ETBusiness Wire
Puma Biotechnology Reports Second Quarter Financial Results
Press releaseMay 8, 4:05 PM ETBusiness Wire
Puma Biotechnology Reports First Quarter Financial Results
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
Press releaseFeb 27, 4:05 PM ETBusiness Wire
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
Press releaseNov 20, 8:57 AM ETBusiness Wire
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcript

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Q2 Adj. EPS $0.19 Beats $0.04 Estimate, Sales $53.600M Beat $53.000M Estimate

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Q1 Adj. EPS $(0.04) Beats $(0.13) Estimate, Sales $44.800M Beat $42.000M Estimate

Puma Biotechnology Reports First Quarter 2026 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

12 Health Care Stocks Moving In Friday's Intraday Session

UPDATE: Puma Biotechnology Q4 Adj. EPS $0.29 Beats $0.23 Estimate, Sales $75.500M Beat $68.600M Estimate

Puma Biotechnology Q4 Earnings Report: What Investors Need to Know

Puma Biotechnology Q4 Adj. EPS $0.30 Beats $0.23 Estimate, Sales $75.500M Beat $68.600M Estimate

Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results

Earnings Scheduled For February 26, 2026

Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

12 Health Care Stocks Moving In Monday's Intraday Session

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Q3 Adj. EPS $0.21 Beats $0.04 Estimate, Sales $54.500M Beat $51.000M Estimate

Puma Biotechnology Reports Third Quarter 2025 Financial Results

Earnings Scheduled For November 6, 2025

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Second Quarter Financial Results

Puma Biotechnology Reports First Quarter Financial Results

Earnings Scheduled For May 8, 2025

Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer